Loading…
Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25...
Saved in:
Published in: | Infection and immunity 1998-05, Vol.66 (5), p.1891-1897 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643 |
---|---|
cites | cdi_FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643 |
container_end_page | 1897 |
container_issue | 5 |
container_start_page | 1891 |
container_title | Infection and immunity |
container_volume | 66 |
creator | GU, X.-X JING CHEN BARENKAMP, S. J ROBBINS, J. B TSAI, C.-M LIM, D. J BATTEY, J |
description | Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases. |
doi_str_mv | 10.1128/iai.66.5.1891-1897.1998 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_108140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16387220</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643</originalsourceid><addsrcrecordid>eNpVUctuFDEQtBAoLIFPQMwBITjMYHv8POQQIh4rBXEAzlavHzuOZseLPRsRznw4HrJawaVb7arqdnch9ILgjhCq3kaInRAd74jSpK1BdkRr9QCtCNaq5ZzSh2iFMdGt5kI-Rk9KuaklY0ydoTPNZY-FWKHfX--mefAllgYm19gBMtjZ5_gL5pimJoVmjPuUxrhNBeyCR-fbDRRf2Wm6OWxh9lVcmtsKx8k3tjaK7u9rSLn5nDL89OMIzet3GaYBdkvxptJmyHmAMZan6FGAsfhnx3yOvn94_-3qU3v95eP66vK6tUySubWAmeWAe-eDBKultYJjCA6oYyQAcdJxJ0Bh7DHYoLT2jnJbj2HxRrD-HF3c990fNjvvrJ_mDKPZ57iDfGcSRPM_MsXBbNOtIVgRhqv-1VGf04-DL7PZxWKXdSafDsUQ0StJ6UKU90SbUynZh9MMgs3in1lfro0QhpvFvyVIs_hXlc___eJJdzSs4i-POBQLY6gXtbGcaJRypons_wBCQKnn</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16387220</pqid></control><display><type>article</type><title>Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis</title><source>American Society for Microbiology Journals</source><source>PubMed Central</source><creator>GU, X.-X ; JING CHEN ; BARENKAMP, S. J ; ROBBINS, J. B ; TSAI, C.-M ; LIM, D. J ; BATTEY, J</creator><creatorcontrib>GU, X.-X ; JING CHEN ; BARENKAMP, S. J ; ROBBINS, J. B ; TSAI, C.-M ; LIM, D. J ; BATTEY, J</creatorcontrib><description>Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases.</description><identifier>ISSN: 0019-9567</identifier><identifier>EISSN: 1098-5522</identifier><identifier>DOI: 10.1128/iai.66.5.1891-1897.1998</identifier><identifier>PMID: 9573066</identifier><identifier>CODEN: INFIBR</identifier><language>eng</language><publisher>Washington, DC: American Society for Microbiology</publisher><subject>Animals ; Antibodies, Bacterial - blood ; Bacterial Vaccines - immunology ; Bacteriology ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; Immune Sera - immunology ; Lipopolysaccharides - immunology ; Mice ; Microbial Immunity and Vaccines ; Microbiology ; Moraxella (Branhamella) catarrhalis - immunology ; Rabbits ; Tetanus Toxoid - immunology ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Conjugate - immunology ; Vaccines, Synthetic - immunology</subject><ispartof>Infection and immunity, 1998-05, Vol.66 (5), p.1891-1897</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright © 1998, American Society for Microbiology 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643</citedby><cites>FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC108140/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC108140/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,3186,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2254917$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9573066$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GU, X.-X</creatorcontrib><creatorcontrib>JING CHEN</creatorcontrib><creatorcontrib>BARENKAMP, S. J</creatorcontrib><creatorcontrib>ROBBINS, J. B</creatorcontrib><creatorcontrib>TSAI, C.-M</creatorcontrib><creatorcontrib>LIM, D. J</creatorcontrib><creatorcontrib>BATTEY, J</creatorcontrib><title>Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis</title><title>Infection and immunity</title><addtitle>Infect Immun</addtitle><description>Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases.</description><subject>Animals</subject><subject>Antibodies, Bacterial - blood</subject><subject>Bacterial Vaccines - immunology</subject><subject>Bacteriology</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Immune Sera - immunology</subject><subject>Lipopolysaccharides - immunology</subject><subject>Mice</subject><subject>Microbial Immunity and Vaccines</subject><subject>Microbiology</subject><subject>Moraxella (Branhamella) catarrhalis - immunology</subject><subject>Rabbits</subject><subject>Tetanus Toxoid - immunology</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Conjugate - immunology</subject><subject>Vaccines, Synthetic - immunology</subject><issn>0019-9567</issn><issn>1098-5522</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNpVUctuFDEQtBAoLIFPQMwBITjMYHv8POQQIh4rBXEAzlavHzuOZseLPRsRznw4HrJawaVb7arqdnch9ILgjhCq3kaInRAd74jSpK1BdkRr9QCtCNaq5ZzSh2iFMdGt5kI-Rk9KuaklY0ydoTPNZY-FWKHfX--mefAllgYm19gBMtjZ5_gL5pimJoVmjPuUxrhNBeyCR-fbDRRf2Wm6OWxh9lVcmtsKx8k3tjaK7u9rSLn5nDL89OMIzet3GaYBdkvxptJmyHmAMZan6FGAsfhnx3yOvn94_-3qU3v95eP66vK6tUySubWAmeWAe-eDBKultYJjCA6oYyQAcdJxJ0Bh7DHYoLT2jnJbj2HxRrD-HF3c990fNjvvrJ_mDKPZ57iDfGcSRPM_MsXBbNOtIVgRhqv-1VGf04-DL7PZxWKXdSafDsUQ0StJ6UKU90SbUynZh9MMgs3in1lfro0QhpvFvyVIs_hXlc___eJJdzSs4i-POBQLY6gXtbGcaJRypons_wBCQKnn</recordid><startdate>19980501</startdate><enddate>19980501</enddate><creator>GU, X.-X</creator><creator>JING CHEN</creator><creator>BARENKAMP, S. J</creator><creator>ROBBINS, J. B</creator><creator>TSAI, C.-M</creator><creator>LIM, D. J</creator><creator>BATTEY, J</creator><general>American Society for Microbiology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>19980501</creationdate><title>Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis</title><author>GU, X.-X ; JING CHEN ; BARENKAMP, S. J ; ROBBINS, J. B ; TSAI, C.-M ; LIM, D. J ; BATTEY, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antibodies, Bacterial - blood</topic><topic>Bacterial Vaccines - immunology</topic><topic>Bacteriology</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Immune Sera - immunology</topic><topic>Lipopolysaccharides - immunology</topic><topic>Mice</topic><topic>Microbial Immunity and Vaccines</topic><topic>Microbiology</topic><topic>Moraxella (Branhamella) catarrhalis - immunology</topic><topic>Rabbits</topic><topic>Tetanus Toxoid - immunology</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Conjugate - immunology</topic><topic>Vaccines, Synthetic - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GU, X.-X</creatorcontrib><creatorcontrib>JING CHEN</creatorcontrib><creatorcontrib>BARENKAMP, S. J</creatorcontrib><creatorcontrib>ROBBINS, J. B</creatorcontrib><creatorcontrib>TSAI, C.-M</creatorcontrib><creatorcontrib>LIM, D. J</creatorcontrib><creatorcontrib>BATTEY, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection and immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GU, X.-X</au><au>JING CHEN</au><au>BARENKAMP, S. J</au><au>ROBBINS, J. B</au><au>TSAI, C.-M</au><au>LIM, D. J</au><au>BATTEY, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis</atitle><jtitle>Infection and immunity</jtitle><addtitle>Infect Immun</addtitle><date>1998-05-01</date><risdate>1998</risdate><volume>66</volume><issue>5</issue><spage>1891</spage><epage>1897</epage><pages>1891-1897</pages><issn>0019-9567</issn><eissn>1098-5522</eissn><coden>INFIBR</coden><abstract>Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases.</abstract><cop>Washington, DC</cop><pub>American Society for Microbiology</pub><pmid>9573066</pmid><doi>10.1128/iai.66.5.1891-1897.1998</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0019-9567 |
ispartof | Infection and immunity, 1998-05, Vol.66 (5), p.1891-1897 |
issn | 0019-9567 1098-5522 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_108140 |
source | American Society for Microbiology Journals; PubMed Central |
subjects | Animals Antibodies, Bacterial - blood Bacterial Vaccines - immunology Bacteriology Biological and medical sciences Female Fundamental and applied biological sciences. Psychology Immune Sera - immunology Lipopolysaccharides - immunology Mice Microbial Immunity and Vaccines Microbiology Moraxella (Branhamella) catarrhalis - immunology Rabbits Tetanus Toxoid - immunology Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Conjugate - immunology Vaccines, Synthetic - immunology |
title | Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T09%3A40%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20characterization%20of%20lipooligosaccharide-based%20conjugates%20as%20vaccine%20candidates%20for%20Moraxella%20(Branhamella)%20catarrhalis&rft.jtitle=Infection%20and%20immunity&rft.au=GU,%20X.-X&rft.date=1998-05-01&rft.volume=66&rft.issue=5&rft.spage=1891&rft.epage=1897&rft.pages=1891-1897&rft.issn=0019-9567&rft.eissn=1098-5522&rft.coden=INFIBR&rft_id=info:doi/10.1128/iai.66.5.1891-1897.1998&rft_dat=%3Cproquest_pubme%3E16387220%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c471t-ca04c5a03def7ac97cc650afda2d41fa1d7d5d6a800e0acf899ed25c552c0b643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=16387220&rft_id=info:pmid/9573066&rfr_iscdi=true |